The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Ritschka, Birgit,1985-
- dc.contributor.author Knauer-Meyer, Tania
- dc.contributor.author Sampaio Gonçalves, Daniel
- dc.contributor.author Mas, Alba
- dc.contributor.author Plassat, Jean-Luc
- dc.contributor.author Durik, Matej
- dc.contributor.author Jacobs, Hugues
- dc.contributor.author Pedone, Elisa, 1985-
- dc.contributor.author Di Vicino, Umberto
- dc.contributor.author Cosma, Maria Pia, 1970-
- dc.contributor.author Keyes, William M., 1973-
- dc.date.accessioned 2020-05-19T10:24:42Z
- dc.date.available 2020-05-19T10:24:42Z
- dc.date.issued 2020
- dc.description.abstract Young mammals possess a limited regenerative capacity in some tissues, which is lost upon maturation. We investigated whether cellular senescence might play a role in such loss during liver regeneration. We found that following partial hepatectomy, the senescence-associated genes p21, p16Ink4a, and p19Arf become dynamically expressed in different cell types when regenerative capacity decreases, but without a full senescent response. However, we show that treatment with a senescence-inhibiting drug improves regeneration, by disrupting aberrantly prolonged p21 expression. This work suggests that senescence may initially develop from heterogeneous cellular responses, and that senotherapeutic drugs might be useful in promoting organ regeneration.
- dc.description.sponsorship Work in the Keyes lab was funded in part by grants from the Spanish Ministry for Economy and Competitiveness (SAF2013-49082-P), La Fondation Recherche Medicale (FRM) (AJE20160635985), Fondation ARC (PJA20181208104), IDEX Attractivité-University of Strasbourg (IDEX2017), and La Fondation Schlumberger pour l'Education et la Recherche (FSER) (FSER 19-Year 2018), and ANR (ANR-19-CE13-0023-03). Work was also supported by grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d'Avenir (ANR-10-IDEX-0002-02)
- dc.format.mimetype application/pdf
- dc.identifier.citation Ritschka B, Knauer-Meyer T, Gonçalves DS, Mas A, Plassat JL, Durik M et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes Dev. 2020 Apr 1; 34(7-8): 489-494. DOI: 10.1101/gad.332643.119
- dc.identifier.doi http://dx.doi.org/10.1101/gad.332643.119
- dc.identifier.issn 0890-9369
- dc.identifier.uri http://hdl.handle.net/10230/44600
- dc.language.iso eng
- dc.publisher Cold Spring Harbor Laboratory Press (CSHL Press)
- dc.relation.ispartof Genes & Development. 2020 Apr 1;34(7-8):489-94
- dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2013-49082-P
- dc.rights Published originally by Cold Spring Harbor Laboratory Press at http://dx.doi.org/10.1101/gad.332643.119. Beginning six months from the full-issue publication date, articles are distributed under the Creative Commons Attribution-Non-Commercial 4.0 International License (CC-BY-NC), as described at http://creativecommons.org/licenses/by-nc/4.0/. This license permits non-commercial use, including reproduction, adaptation, and distribution of the article provided the original author and source are credited
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.other Fetge -- Regeneració
- dc.subject.other Cèl·lules hepàtiques
- dc.subject.other Envelliment
- dc.subject.other Senilítics
- dc.title The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion